Everything to know about GLP-1 medications: how they work, who qualifies, the risks, and which versions are FDA-approved for weight loss and diabetes.
Quick Answer: What Are GLP-1 Medications?
GLP-1 medications have transformed how we treat obesity and Type 2 diabetes, becoming some of the most prescribed, and most discussed, medications in modern medicine. If you're considering whether a GLP-1 might be right for you, this guide covers everything from how they work to who qualifies, what the risks are, and which versions are FDA-approved.
What Are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a naturally occurring hormone in your body. This hormone, released by your intestines after eating, helps regulate blood sugar, slows digestion, and signals to your brain that you're full.
Originally developed to treat Type 2 diabetes, GLP-1 medications have emerged as one of the most effective tools available for chronic weight management. Their ability to improve metabolic health while supporting significant weight loss has made them a cornerstone of modern obesity medicine.
How Do GLP-1 Medications Work?
GLP-1 receptor agonists support weight loss and blood sugar control through several mechanisms working together:
- Slowing gastric emptying so food stays in your stomach longer, increasing fullness
- Suppressing appetite by acting on hunger centers in the brain
- Improving insulin response by stimulating insulin release when blood sugar is elevated
- Reducing glucagon release, a hormone that raises blood sugar
- Supporting weight regulation through the combined metabolic effects
The result is reduced food intake, better blood sugar control, and, for most patients, sustained, meaningful weight loss.
GLP-1 Statistics: The Numbers You Should Know
Usage and Adoption
- Approximately 1 in 8 U.S. adults (about 12%) has used a GLP-1 medication, according to a 2024 KFF Health Tracking Poll
- About 6% of U.S. adults are currently taking a GLP-1 medication
- Among those who have taken GLP-1s, roughly 4 in 10 cite weight loss as the primary reason
- The global GLP-1 market is projected to exceed $100 billion by 2030
Weight Loss Outcomes from Clinical Trials
- Semaglutide (Wegovy): Adults in the STEP 1 trial lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo
- Tirzepatide (Zepbound): Adults in the SURMOUNT-1 trial lost an average of 20.9% of body weight at the highest dose over 72 weeks
- Liraglutide (Saxenda): Average weight loss of approximately 8% of body weight over 56 weeks
Health Outcomes Beyond Weight
- The SELECT trial showed semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with overweight or obesity and pre-existing cardiovascular disease
- GLP-1s show significant improvements in HbA1c levels, blood pressure, and lipid profiles
- Emerging research suggests benefits for kidney disease progression, sleep apnea, and even certain neurological conditions
The Scope of the Problem GLP-1s Address
- More than 40% of U.S. adults have obesity (CDC)
- Approximately 38 million Americans have diabetes, with 90-95% having Type 2
- An estimated 96 million U.S. adults have prediabetes
FDA-Approved GLP-1 Medications
GLP-1 Medications FDA-Approved for Chronic Weight Management
Only three GLP-1 medications are currently FDA-approved specifically for weight loss:
Wegovy (semaglutide)
- Approved: 2021
- Manufacturer: Novo Nordisk
- Administration: Weekly subcutaneous injection
- Approved for: Adults and adolescents 12+ with obesity, or adults with overweight and at least one weight-related condition
- Also approved (2024) to reduce cardiovascular risk in adults with cardiovascular disease and obesity or overweight
Zepbound (tirzepatide)
- Approved: November 2023
- Manufacturer: Eli Lilly
- Administration: Weekly subcutaneous injection
- Note: Tirzepatide is a dual GIP/GLP-1 receptor agonist (it activates two hormone pathways)
- Approved for: Adults with obesity, or adults with overweight and at least one weight-related condition
- Also approved (2024) for moderate-to-severe obstructive sleep apnea in adults with obesity
Saxenda (liraglutide)
- Approved: 2014
- Manufacturer: Novo Nordisk
- Administration: Daily subcutaneous injection
- Approved for: Adults and adolescents 12+ with obesity, or adults with overweight and weight-related conditions
GLP-1 Medications FDA-Approved for Type 2 Diabetes
These GLP-1s are approved for Type 2 diabetes management. Weight loss often occurs as a benefit, but using them for weight loss alone is considered "off-label":
- Ozempic (semaglutide): Weekly injection, approved 2017
- Rybelsus (semaglutide): Daily oral tablet, approved 2019
- Mounjaro (tirzepatide): Weekly injection, approved 2022
- Trulicity (dulaglutide): Weekly injection, approved 2014
- Victoza (liraglutide): Daily injection, approved 2010
- Byetta (exenatide): Twice-daily injection, approved 2005
- Bydureon BCise (exenatide extended-release): Weekly injection
Important: Only Wegovy, Zepbound, and Saxenda are FDA-approved for weight management. Diabetes-indicated GLP-1s like Ozempic and Mounjaro share active ingredients with their weight-loss counterparts but are prescribed off-label when used for weight loss.
Who Should Consider GLP-1 Medications?
GLP-1 medications are not for everyone. Clinical guidelines identify specific groups who are most likely to benefit.
Candidates for GLP-1 Weight Management
You may be a candidate for GLP-1 weight loss medication if you have:
- A BMI of 30 or higher (clinical obesity), or
- A BMI of 27 or higher with at least one weight-related condition, such as:
- Type 2 diabetes or prediabetes
- High blood pressure (hypertension)
- High cholesterol or dyslipidemia
- Obstructive sleep apnea
- Cardiovascular disease
- Non-alcoholic fatty liver disease (NAFLD/MASLD)
Candidates for GLP-1 Diabetes Treatment
GLP-1s may be appropriate if you:
- Have been diagnosed with Type 2 diabetes
- Need additional support beyond lifestyle changes and metformin
- Would benefit from a medication that also supports weight management
- Have cardiovascular disease (certain GLP-1s offer cardiovascular protection)
Who Should NOT Take GLP-1 Medications
GLP-1s are contraindicated or require special caution in people who:
- Have a personal or family history of medullary thyroid carcinoma (MTC)
- Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Have had a serious allergic reaction to a GLP-1 medication
- Are pregnant, planning pregnancy, or breastfeeding
- Have a history of severe gastrointestinal disease such as gastroparesis
- Have a history of pancreatitis (caution required, individualized decision)
- Have Type 1 diabetes (GLP-1s are not approved for Type 1)
Risks and Side Effects of GLP-1 Medications
Common Side Effects
The most frequently reported side effects involve the digestive system and typically improve as your body adjusts:
- Nausea (most common)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Reduced appetite
- Fatigue
- Headache
Slow dose titration (starting low and increasing gradually) significantly reduces these side effects for most patients.
Serious Risks to Be Aware Of
Pancreatitis. GLP-1 medications carry a warning about acute pancreatitis. Severe, persistent abdominal pain requires immediate medical attention.
Gallbladder disease. Gallstones and gallbladder inflammation occur at higher rates in GLP-1 users, especially with rapid weight loss.
Thyroid C-cell tumors. GLP-1s carry a boxed warning due to thyroid C-cell tumors observed in rodent studies. The relevance to humans remains unclear, but these medications are not recommended for those with a personal or family history of MTC.
Hypoglycemia (low blood sugar). Risk increases when GLP-1s are combined with insulin or sulfonylureas in people with diabetes.
Kidney problems. Severe nausea and vomiting can lead to dehydration and acute kidney injury.
Diabetic retinopathy. Some studies have noted worsening of pre-existing diabetic eye disease.
Vision concerns. Recent research has explored a potential link between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), though more research is needed.
Loss of lean muscle mass. Significant weight loss can include muscle loss, which makes adequate protein intake and resistance training essential during treatment.
Anesthesia considerations. Because GLP-1s slow gastric emptying, surgical patients may need to pause their medication before procedures to reduce aspiration risk. Always inform your surgical team.
Long-Term Considerations
- Weight regain after stopping. Studies show stopping GLP-1 medications typically leads to significant weight regain. Many experts now view obesity as a chronic condition requiring long-term treatment, similar to high blood pressure.
- Cost and access. Monthly costs range from approximately $1,000 to $1,400 without insurance coverage.
- Supply shortages. Several GLP-1 medications have experienced periodic shortages, though supply has improved.
- Compounded versions. The FDA has issued warnings about safety concerns with compounded GLP-1s, which are not FDA-approved. Always source GLP-1 medications through reputable, licensed medical providers.
Why Lifestyle Changes Matter on GLP-1 Therapy
GLP-1 medications work best as part of a comprehensive approach to health. At Amsara Health, we view GLP-1s as powerful tools, not magic solutions, and we always pair medical therapy with thoughtful nutrition and movement guidance.
Nutrition During GLP-1 Treatment
- Prioritize protein (typically 0.6-0.8 grams per pound of goal body weight) to preserve lean muscle mass
- Emphasize whole foods rich in fiber, including vegetables, fruits, legumes, and whole grains
- Stay hydrated. Reduced appetite often dampens thirst signals as well
- Eat smaller, more frequent meals to manage GI side effects and maintain energy
- Limit highly processed foods, added sugars, and alcohol
Movement and Exercise
Regular activity is critical when taking GLP-1 medications:
- Resistance training 2-3 times per week to preserve and build lean muscle
- Cardiovascular exercise for heart health and additional metabolic benefit
- Daily movement through walking, stretching, and breaking up sedentary time
Behavioral and Mental Health Support
Sustainable weight management addresses the whole person:
- Stress management
- Quality sleep (7-9 hours nightly)
- Awareness of emotional eating patterns
- Building habits that last beyond the medication itself
Amsara Health's Medically Supervised Weight Loss Program
At Amsara Health, we offer a medically supervised weight loss program that combines evidence-based GLP-1 therapy with personalized lifestyle support. Our philosophy is straightforward: GLP-1 medications are powerful tools, but they work best when paired with healthy eating, regular movement, and ongoing medical guidance.
Our program includes:
- Initial medical evaluation to determine candidacy and the right medication for you
- Personalized treatment plans tailored to your health profile and goals
- Ongoing medical supervision throughout your treatment
- Nutrition guidance focused on sustainable healthy eating
- Exercise recommendations designed to preserve muscle and improve fitness
- Education and support to build lasting changes that extend beyond the medication
GLP-1s can be transformative for the right candidate, but they should always be used under qualified medical supervision and as part of a broader commitment to overall wellness.
Frequently Asked Questions About GLP-1 Medications
How long do I need to take GLP-1 medications?
Most experts now consider obesity a chronic condition. GLP-1 therapy may be long-term for many patients, since stopping the medication typically leads to weight regain. Your provider can help you understand what long-term treatment looks like for your situation.
Can I take GLP-1s if I don't have diabetes?
Yes. Wegovy, Zepbound, and Saxenda are FDA-approved for weight management in adults (and some adolescents) without diabetes who meet specific BMI and health criteria.
Are compounded GLP-1s safe?
Compounded versions of GLP-1 medications became more common during recent shortages but are not FDA-approved. The FDA has issued multiple safety warnings about compounded GLP-1s. Always source these medications through reputable, licensed medical providers.
How quickly will I see results on a GLP-1?
Most patients notice reduced appetite within the first few weeks. Meaningful weight loss typically begins within the first 1-2 months and continues over 12-18 months, depending on the medication and individual response.
Will my insurance cover a GLP-1?
Coverage varies widely. Many plans cover GLP-1s for Type 2 diabetes but not weight loss. Medicare currently does not cover GLP-1s for weight loss alone, though policy is evolving. Your medical team can help navigate coverage questions.
What happens if I stop taking a GLP-1?
Research consistently shows that stopping GLP-1 therapy is associated with significant weight regain, often two-thirds or more of the weight lost within a year. This is one reason obesity medicine increasingly treats these medications like other chronic-disease therapies.
Is a GLP-1 Right for You?
GLP-1 medications represent one of the most significant advances in metabolic medicine in decades. They offer real, sustained results for people struggling with obesity and Type 2 diabetes. But they aren't a quick fix, and they aren't right for everyone.
The best way to determine if a GLP-1 medication is appropriate for your unique health profile is to speak with a qualified medical provider who can evaluate your full health picture, discuss your goals, and design a treatment plan that supports lasting wellness.
To learn more about Amsara Health's medically supervised weight loss program, and to find out if a GLP-1 might be right for you, schedule a consultation today.
This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new medication or treatment plan.